Kolistimetatnatrium Noridem

Colistimethate Sodium, the active ingredient in Kolistimetatnatrium Noridem, is a Polymyxin antibiotic presented as an inhalation solution for inhalation use. It treats chronic lung infection due to Pseudomonas aeruginosa in patients with cystic fibrosis.

GNH USA supplies Kolistimetatnatrium Noridem as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Kolistimetatnatrium Noridem is used to manage chronic bacterial lung disease caused by Pseudomonas aeruginosa in cystic fibrosis patients.

- Chronic lung infection due to Pseudomonas aeruginosa in cystic fibrosis: reduces bacterial load and helps preserve lung function.

Adverse reactions may occur with inhaled colistimethate sodium.

Common Side Effects: - Cough - Bronchospasm - Throat irritation - Taste disturbance - Nausea - Mild headache

Serious or Rare Side Effects: - Respiratory failure - Anaphylactic reaction - Nephrotoxicity (systemic exposure) - Neurotoxicity (paresthesia, seizures) - Hemoptysis - Severe bronchial obstruction

Use of inhaled colistimethate sodium requires careful monitoring and patient education.

- Renal function monitoring: assess serum creatinine before and during therapy. - Auditory monitoring: watch for signs of ototoxicity, especially with prolonged use. - Bronchospasm risk: pre‑treat with a bronchodilator if patient has reactive airway disease. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Concomitant nephrotoxic drugs: avoid or adjust dosage. - Store at room temperature: keep in original container, protect from moisture and light.

Colistimethate sodium may interact with other medicines, affecting safety or efficacy.

Major Interactions (Avoid): - Aminoglycosides (e.g., gentamicin): increased risk of nephrotoxicity. - Vancomycin: additive renal toxicity. - Neuromuscular blocking agents: may potentiate respiratory muscle weakness.

Moderate Interactions (Monitor Closely): - NSAIDs: may modestly increase renal risk. - Rifampin: may reduce colistin plasma concentrations.